Materias dentro de su búsqueda.
Mostrando 2,561 - 2,580 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.30s Limitar resultados
  1. 2561
    Publicado 1995
    “…Synthetic peptide analogues of sequences in the HER-2 protooncogene (HER-2) were selected based on the presence of HLA-A2.1 anchor motifs to identify the epitopes on HER-2 recognized by ovarian tumor-reactive CTL. 19 synthetic peptides were evaluated for recognition by four HLA- A2 ovarian-specific cytotoxic T lymphocyte (CTL) lines obtained from leukocytes associated with ovarian tumors. …”
    Enlace del recurso
    Enlace del recurso
    Texto
    Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
  2. 2562
    “…The ability of interleukin (IL)-12 to prevent tumors when administered to individuals with a genetic risk of cancer was studied in two lines of transgenic mice expressing rat HER-2/neu oncogene in the mammary gland. Female BALB/c (H-2(d)) mice carrying the activated HER-2/ neu oncogene show no morphological abnormalities of the mammary gland until 3 wk of age. …”
    Enlace del recurso
    Enlace del recurso
    Texto
    Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice
  3. 2563
    por Menendez, Javier A, Lupu, Ruth
    Publicado 2007
    “…Although neither kinase-dead human epidermal growth factor receptor (HER)3 nor orphan HER2 can be activated by HER-related ligands on their own, the formation of HER2/HER3 heterodimers creates the most mitogenic and transforming receptor complex within the HER (erbB) family of transmembrane receptor tyrosine kinases. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?
  4. 2564
    “…We found a significant correlation between FOXM1 expression and the HER2 status determined by HER2 immunohistochemistry (P < 0.05). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer
  5. 2565
    “…BACKGROUND: The status of the EGFR and HER2-neu genes has not been fully defined in ovarian cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers
  6. 2566
    “…In this study, we explore the therapeutic potential of lapatinib a selective inhibitor of both the EGFR and HER2 tyrosine kinases for the treatment of endometrial cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
  7. 2567
    por BROOKES, BARBARA
    Publicado 2008
    Enlace del recurso
    Enlace del recurso
    Texto
    A Corresponding Community: Dr Agnes Bennett and her Friends from the Edinburgh Medical College for Women of the 1890s
  8. 2568
    “…HER2/neu overexpression is a driving force in the carcinogenesis of several human cancers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway
  9. 2569
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    HER2 (ErbB2) receptors, a potential therapeutic target in squamous cell carcinoma of oesophagus
  10. 2570
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer
  11. 2571
    “…Although several studies have found overexpression of epidermal growth factor receptor (EGFR) proteins EGFR and Her-2 in head and neck cancers, the clinical relevance of the finding varies. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis
  12. 2572
    “…BACKGROUND: Dysregulated PI3K/Akt signaling occurs commonly in breast cancers and is due to HER2 amplification, PI3K mutation or PTEN inactivation. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
  13. 2573
    “…Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are among the most often targeted proteins. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: Implications for targeted radiotherapy
  14. 2574
    “…We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status significantly affects the survival in this otherwise very good prognostic group. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours
  15. 2575
    “…A positive correlation of human epidermal growth factor receptor 2 (HER2) amplification and LI has been described, which was associated with a more favorable outcome. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
  16. 2576
    “…INTRODUCTION: Classification of breast cancers according to the HER-2 oncogene status is of central importance in the selection of post-surgical therapies. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005
  17. 2577
    “…INTRODUCTION: The prognostic value of HER2 expression in patients with advanced non-small cell lung cancer remains controversial. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients
  18. 2578
    “…Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2). Results of a phase III study comparing lapatinib plus capecitabine with capecitabine alone in women with ErbB2-overexpressing advanced breast cancer previously treated with an anthracycline, a taxane, and trastuzumab were reported early based on superiority of the combination in prolonging time to tumor progression (TTP). …”
    Enlace del recurso
    Enlace del recurso
    Texto
    Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
  19. 2579
    “…METHODS: HER2 status was tested in 33 mucinous carcinomas and 16 mucinous borderline ovarian tumors (BOT)). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy
  20. 2580
    “…Her2-induced signaling pathways include MAPK and PI3K/Akt, of which the latter has been shown to be critical for Her2(+) breast cancer cell growth and survival. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Her2 Activates NF-κB and Induces Invasion Through the Canonical Pathway Involving IKKα
Herramientas de búsqueda: RSS